Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Gaudy-Marqueste

Showing results (31-40 of 43) with videos related to

Pageof 5
Sort By:
Annales De Dermatologie Et De Venereologie|December 16, 2017
[On the attractiveness of a university-hospital career in medicine: Obstacles and solutions. The teachers' perspective]M Samimi, B Dreno, S Aractingi, et al.
Cancer Immunology, Immunotherapy : CII|May 21, 2022
Treatment with a retinoic acid-inducible gene I (RIG-I) agonist as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors: results from two phase 1 studiesV Moreno, E Calvo, M R Middleton, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|June 22, 2016
Predictors of long-term drug survival for infliximab in psoriasisQ Magis, D Jullien, C Gaudy-Marqueste, et al.
ESMO Open|May 26, 2026
Concordance of pathologic response assessment between local and central review in melanoma: a post hoc analysis of KEYMAKER-U02 substudy 02CM Tetzlaff, J M Taube, G V Long, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|August 23, 2021
Position statement on classification of basal cell carcinomas. Part 2: EADO proposal for new operational staging system adapted to basal cell carcinomasJ J Grob, C Gaudy-Marqueste, A Guminski, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|August 25, 2021
Position statement on classification of basal cell carcinomas. Part 1: unsupervised clustering of experts as a way to build an operational classification of advanced basal cell carcinoma based on pattern recognitionJ J Grob, A Guminski, J Malvehy, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 21, 2024
Pembrolizumab versus ipilimumab for advanced melanoma: 10-year follow-up of the phase III KEYNOTE-006 studyG V Long, M S Carlino, C McNeil, et al.
ESMO Open|May 9, 2025
Early switch from run-in with targeted to immunotherapy in advanced BRAF<sup>V600</sup>-positive melanoma: final results of the randomised phase II ImmunoCobiVem trialE Livingstone, H J Gogas, L Kandolf, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 9, 2020
ESMO consensus conference recommendations on the management of locoregional melanoma: under the auspices of the ESMO Guidelines CommitteeO Michielin, A van Akkooi, P Lorigan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 9, 2020
ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines CommitteeU Keilholz, P A Ascierto, R Dummer, et al.
Pageof 5

Showing results (31-40 of 43) with videos related to

Sort By:
Pageof 5
Annales De Dermatologie Et De Venereologie|December 16, 2017
[On the attractiveness of a university-hospital career in medicine: Obstacles and solutions. The teachers' perspective]M Samimi, B Dreno, S Aractingi, et al.
Cancer Immunology, Immunotherapy : CII|May 21, 2022
Treatment with a retinoic acid-inducible gene I (RIG-I) agonist as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors: results from two phase 1 studiesV Moreno, E Calvo, M R Middleton, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|June 22, 2016
Predictors of long-term drug survival for infliximab in psoriasisQ Magis, D Jullien, C Gaudy-Marqueste, et al.
ESMO Open|May 26, 2026
Concordance of pathologic response assessment between local and central review in melanoma: a post hoc analysis of KEYMAKER-U02 substudy 02CM Tetzlaff, J M Taube, G V Long, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|August 23, 2021
Position statement on classification of basal cell carcinomas. Part 2: EADO proposal for new operational staging system adapted to basal cell carcinomasJ J Grob, C Gaudy-Marqueste, A Guminski, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|August 25, 2021
Position statement on classification of basal cell carcinomas. Part 1: unsupervised clustering of experts as a way to build an operational classification of advanced basal cell carcinoma based on pattern recognitionJ J Grob, A Guminski, J Malvehy, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 21, 2024
Pembrolizumab versus ipilimumab for advanced melanoma: 10-year follow-up of the phase III KEYNOTE-006 studyG V Long, M S Carlino, C McNeil, et al.
ESMO Open|May 9, 2025
Early switch from run-in with targeted to immunotherapy in advanced BRAF<sup>V600</sup>-positive melanoma: final results of the randomised phase II ImmunoCobiVem trialE Livingstone, H J Gogas, L Kandolf, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 9, 2020
ESMO consensus conference recommendations on the management of locoregional melanoma: under the auspices of the ESMO Guidelines CommitteeO Michielin, A van Akkooi, P Lorigan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 9, 2020
ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines CommitteeU Keilholz, P A Ascierto, R Dummer, et al.
Pageof 5